# Biocon

Biosimilars + local build — EMA-approved India mAbs site.

Source: https://en.bioecon.ru/companies/biocon/
Updated: 2026-06-24

- Country: India

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | Rs 4,150 crore (~USD 460 million) equity fundraise via Qualified Institutions Placement (QIP) concluded in January 2026 | https://www.bioconbiologics.com/biocon-limited-concludes-rs-4150-crore-usd-460-million-equity-fundraise-through-a-%C7%ABualified-institutions-placement-%C7%ABip/ |
| Production site | 350,000 sq. ft. mAbs Drug Substance (B3) facility at Biocon Park, Bengaluru, India | https://www.biocon.com/businesses/biosimilars/global-scale-manufacturing/, https://www.bioprocessintl.com/facilities-capacity/biocon-expanded-plant-approved-to-make-avastin-biosimilar |
| Capacity | 42,000 L capacity at the Bengaluru mAbs facility | https://www.bioprocessintl.com/facilities-capacity/biocon-expanded-plant-approved-to-make-avastin-biosimilar |
| Regulatory approval | EMA approved for manufacture of biosimilar Bevacizumab and Trastuzumab at Bengaluru mAbs facility | https://www.biocon.com/ema-approves-biocon-biologics-new-mabs-facility-in-india-and-renews-gmp-certifications-for-india-and-malaysia-sites/, https://www.bioprocessintl.com/facilities-capacity/biocon-expanded-plant-approved-to-make-avastin-biosimilar, https://www.prnewswire.com/news-releases/ema-approves-biocon-biologics-new-mabs-facility-in-india-and-renews-gmp-certifications-for-india-and-malaysia-sites-302180507.html |
| Certification | Renewed GMP Certificates of Compliance for Bengaluru and Malaysia sites issued by HPRA on behalf of EMA (as of June 2024) | https://www.biocon.com/ema-approves-biocon-biologics-new-mabs-facility-in-india-and-renews-gmp-certifications-for-india-and-malaysia-sites/, https://www.bioprocessintl.com/facilities-capacity/biocon-expanded-plant-approved-to-make-avastin-biosimilar, https://www.prnewswire.com/news-releases/ema-approves-biocon-biologics-new-mabs-facility-in-india-and-renews-gmp-certifications-for-india-and-malaysia-sites-302180507.html |
| Headcount | 18,200+ total employees (Biocon Group, as of FY2025) | https://www.biocon.com/docs/Biocon_Group_Corporate_Presentation.pdf |
| Revenue | Biocon Limited revenue: USD 1.9 billion; Biocon Biologics revenue: USD 1.1 billion (FY2025) | https://www.biocon.com/docs/Biocon_Group_Corporate_Presentation.pdf, https://www.biocon.com/docs/IR-Presentation-February-2026-no-coverletter.pdf |

Independent sources: bioprocessintl.com, prnewswire.com

## Technologies

- [Biopharmaceuticals & biomedicines](https://en.bioecon.ru/technology/biopharmaceuticals-biomedicines/)
- [Local manufacturing for market access](https://en.bioecon.ru/technology/local-manufacturing-for-market-access/)